1[1]Oparil S, Dyke S, Houris F, et al. Valsartan: a randomized controlled trial to compare the efficacy and safety of 20, 80, 160 and 320 mg with placebo in the management of essential hypertension[J]. Clin Ther, 1996,18(5):797-810.
2[2]Markham A, Goa K L. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension[J]. Drug, 1997,54:299-311.
3[3]Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin Ⅱ antagonist for the treatmnet of essential hyertension, a comparative study of the efficacy and safety against amlodipine[J]. Clin Pharm Ther, 1996,60:341-346.
4[4]Baruch L, Anand I, Cohen I S, et al. Augmented short and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure[J]. Circulation, 1999, 99(20):2658-2664.
5[5]Petra A, Thurmunn, Peter A K, et al. Influence of the angiotenisn Ⅱ antagomist valsartan on left ventricular hypertrophy in patients with essential hypertension[J]. Circulation, 1998,98:2037-2042.
6[6]Ruilope L M, Aldigier J C, Ponticelli C, et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease[J]. J Hypertens, 2000, 18(1):89-95.
7[7]Kohno M, Ohmori K, Nozaki S, et al. Effects of valsartan on angiotensin Ⅱ induced migration of human coronary artery smooth muscle cells[J]. J Hypertens Res, 2000, 23(6):677-681.
